NCT06614179 is a clinical trial in Abdominal Neoplasm, sponsored by Xiangdong Cheng.

Who is sponsoring NCT06614179?

NCT06614179 is sponsored by Xiangdong Cheng.

What condition does NCT06614179 study?

NCT06614179 studies Abdominal Neoplasm.

Is NCT06614179 still recruiting?

NCT06614179 is currently recruiting now. Last updated 26 September 2024.

Last reviewed 2024-09-26 · How we verify

NCT06614179

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established

Recruiting now Last updated 26 September 2024

What this trial tests

trial in Abdominal Neoplasm in 100,000 participants. Currently enrolling.

Timeline

1 July 2024

Primary endpoint
31 December 2029

31 December 2029

Quick facts

Lead sponsor	Xiangdong Cheng
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100,000
Start date	1 July 2024
Primary completion	31 December 2029
Estimated completion	31 December 2029
Sites	2 locations across China

Conditions studied

Abdominal Neoplasm — all drugs for Abdominal Neoplasm →

Sponsor

Xiangdong Cheng — full company profile →

Who can join

Adults 18 to 75, any sex, with Abdominal Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

AI-based large-scale screening of gastric cancer from noncontrast CT imaging.
Hu C, Xia Y, Zheng Z, Cao M, et al · · 2025 · cited 7× · PMID 40555751 · DOI 10.1038/s41591-025-03785-6

Verify or expand the search:

Other recruiting trials for Abdominal Neoplasm

Currently open trials in the same condition.

NCT07113808 — Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China · recruiting

Other Xiangdong Cheng trials

Trials by the same sponsor.

NCT07068516 — Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer · Phase 3 · not yet recruiting
NCT06766305 — QL1706 Combined With SOX Used in Theperioperative Treatment · Phase 1, PHASE2 · recruiting
NCT06610799 — Study of IBI363 in Patients with Advanced First-line Gastric Cancer · Phase 1 · recruiting
NCT06374901 — Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. · Phase 2 · not yet recruiting
NCT06642857 — Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastr · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06614179 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangdong Cheng
Last refreshed: 26 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06614179.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing